Wyszukiwanie preparatu według nazwy

Sulfamethoxazole Trimethoprim Oral Suspension i Niewydolność nerek

Wynik sprawdzenia interakcji między lekiem Sulfamethoxazole Trimethoprim Oral Suspension a chorobą Niewydolność nerek w zakresie bezpieczeństwa przy wspólnym stosowaniu.

Wynik kontroli:

Sulfamethoxazole Trimethoprim Oral Suspension <> Niewydolność nerek

Aktualność: 23.07.2019 Recenzent: Shkutko P.M., k.n.m, in

Przy sprawdzeniu interakcji według miarodajnych źródeł Drugs.com, Rxlist.com, Webmd.com, Medscape.com zostały wykryte przeciwwskazania lub skutki uboczne, które mogą zaszkodzić albo wzmocnić negatywny efekt podczas stosowania leku przy tej chorobie towarzyszącej.

Konsument:

Sulfonamidy i ich metabolity są wydalane przez nerki. U pacjentów z niewydolnością nerek może wystąpić zwiększone ryzyko szkodliwego oddziaływania od sulfanamides w związku ze zmniejszeniem klirensu leku. Dawkowanie korekty mogą być potrzebne i zmiany muszą być oparte na stopniu zaburzenia czynności nerek i stopnia ciężkości zakażenia. Ponadto, sulfonamidy mogą powodować co, całkowita w christalluria, w tym URO - i nerkowe choroby, jade, toksyczne nerczyca, krwiomocz, białkomocz, a także podwyższony poziom BUN i kreatyniny. Nawodnienie (8 uncji. szklankę wody z każdej dawki i w ciągu dnia) i odpowiedniej diurezy (> 1,5 l/dzień) należy zapisać w administracji sulfonamida. Testy nerek i badanie moczu powinno odbywać się co tydzień lub tak często, jak stan pacjenta. Rzadko, zalkalizowaniu moczu.

Źródła

Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979): s371-81
Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985): 535-9
Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972): 773-8
Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984): 1467-74
Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970): 561-6
Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975): 171-9
Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970): 250-4
Rieder J, Schwartz DE, Fernex M, et al "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974): 148-98
Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982): 22-118
Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979): s382-7
Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981): 350-7
Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992): 361
Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994): 1605-6
Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980): 405-23
Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972): 483-92
Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979): s382-7
Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987): 81-5
Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988): 483-8
Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984): 125-31
"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn, Kalamazoo, MI.
Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987): 783-4
Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973): 383-7
Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992): 1006-7
Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981): 206-11
Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989): 85-6
Molina J, Belenfant X, Doco-Lecompte T, et al "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991): 587-9
"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.
Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993): 365-7
Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992): 739-40
Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993): 254-6
"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc, Laurelton, NY.
Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985): 285-302
"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories, Nutley, NJ.
Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966): 1-9
Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996): 185-94
Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980): 360-1
Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982): 461-70
Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988): 791-2
Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990): 233-4
Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992): 361
Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979): s367-70
Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988): 72-5
Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974): 112-7
Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978): 57-67
Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972): 539-51
Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990): 2379-84
Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973): 703-12
Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982): 461-70

Sulfamethoxazole Trimethoprim Oral Suspension

Nazwa niezastrzeżona: sulfamethoxazole / trimethoprim

Znak handlowy: Bactrim, Bactrim DS, Bactrim IV, Septra IV, SMZ-TMP DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS

Synonimy: Sulfamethoxazole and trimethoprim, Sulfamethoxazole and Trimethoprim

Czym jest Sulfamethoxazole Trimethoprim Oral Suspension?

Inny lek Usunąć

Sulfamethoxazole Trimethoprim Oral Suspension <> Niewydolność nerek

Aktualność: 23.07.2019 Recenzent: Shkutko P.M., k.n.m, in

Konsument:

Trimetoprim przede wszystkim wyeliminowane nerki. Stężenie trimetoprimu w surowicy krwi może być zwiększone i okres półtrwania jest przeznaczony dla pacjentów z zaburzeniami czynności nerek. Dawkowanie korekty mogą być potrzebne i zmiany muszą być oparte na stopniu zaburzenia czynności nerek, a także nasilenia zakażenia. Producenci zalecają, aby w dawce 50 mg co 12 h. u pacjentów z kreatyniny od 15 do 30 ml/min, a nie podczas stosowania leku u pacjentów z kreatyniny poniżej 15 ml/min.

Źródła

Watson ID, Stewart MJ, Wiles A, McIntosh SJ "Pharmacokinetics of two dosage levels of trimethoprim to "steady-state" in normal volunteers." J Int Med Res 11 (1983): 137-44
Nolte H, Buttner H "Pharmacokinetics of trimethoprim and its combination with sulfamethoxazole in man after single and chronic oral administration." Chemotherapy 18 (1973): 274-84
Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979): s382-7
Ahlmen J, Brorson J-E "Pharmacokinetics of trimethoprim given in single daily doses for three days." Scand J Infect Dis 14 (1982): 143-5
"Product Information. Trimpex (trimethoprim)." Roche Laboratories, Nutley, NJ.
Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978): 57-67
Odlind B, Hartvig P, Fjellstrom KE, Lindstrom B, Bengtsson S "Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods." Eur J Clin Pharmacol 26 (1984): 393-7
Hengstmann JH "Pharmacokinetics of trimethoprim and tetroxoprim: a review." Antibiot Chemother 31 (1982): 211-24
Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973): 383-7
Bergan T, Brodwall EK "Kidney transport in man of sulfamethoxazole and trimethoprim." Chemotherapy 17 (1972): 320-33
Rieder J, Schwartz DE, Fernex M, et al "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974): 148-98